Disorder of Sex Development, 46,XY
Conditions
Brief summary
The goal of this clinical trial is to identify structural variants by Optical Genome Mapping (OGM) in the described participant population. The main questions it aims to answer are: * Identify constitutional structural variants by OGM of DNA extracted from blood leukocytes of patients with DSD for which the molecular diagnosis is inconclusive. * Identify mosaic structural variants (present in a subpopulation of somatic cells only) by OGM of DNA extracted from blood leukocytes of patients with DSD for which the molecular diagnosis is inconclusive. * Compare the diagnostic yields of OGM and of Comparative Genome Hybridization Array (CGH array) methods. * Compare the diagnostic yields of the OGM and of Whole Genome Sequencing (National Sequencing Program), only if performed. Participants will be required to: * a follow-up interview with a physician to review their own and family medical and surgical history, with a focusing on DSD. * An interview to assess their exposure to environmental pollutants during fetal life, using a validated questionnaire. * a blood test with a 5mL tube to perform optical genome mapping analysis.
Detailed description
Patients with severe or moderate disorder of sex development (DSD) with a inconclusive molecular diagnosis will benefit from optical genome mapping analysis. A venous blood sample on ethylenediaminetetraacetic acid (EDTA) tube (5mL) will be taken in order to extract the DNA that will be used for the optical genome mapping analysis.
Interventions
DIAGNOSTIC_TESTIdentify structural variants by Optical Genome Mapping of DNA extracted from blood leukocytes
The one arm of the study will have a venous blood draw as part of the research. 1 EDTA tube of 5mL will be collected.
Sponsors
University Hospital, Montpellier
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Intervention model description
This is a single-center molecular biology pilot study on a single group of 20 patients with a disorder of sex development and inconclusive molecular diagnosis. The 20 blood samples from patients with severe or moderate DSD, with an inconclusive diagnosis will benefit from the Optical Genome Mapping.
Eligibility
Sex/Gender
MALE
Age
6 Months to No maximum
Healthy volunteers
No
Inclusion criteria
* homogeneous XY male karyotype. * patient at least 6 months old * severe to moderate DSD (Prader 1 to 5) for which the molecular diagnosis is inconclusive after a gene panel analysis.
Exclusion criteria
* subject with a homogeneous or mosaic XX, or monosomal X karyotype. * subject with an aneuploidy. * subject with a conclusive molecular diagnosis explaining the observed DSD (i.e. carrier of a causal genotype already well characterized by functional studies)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants with a constitutional structural variants detected by OGM | Day of inclusion | A structural variant, present at the constitutional state in leukocyte DNA, and considered as likely pathogenic or pathogenic, identified by OGM in at least one of the included patients. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants with mosaic structural variants detected by OGM | Day of inclusion | A structural variant, present at the mosaic state in leukocyte DNA (i.e. allelic imbalance less than 0.40), and considered as likely pathogenic or pathogenic, identified by OGM in at least one of the included patients. |
Countries
France
Contacts
Primary ContactFrançoise PARIS, MD PhD
Backup ContactAnne BERGOUGNOUX, PharmD PhD
Outcome results
None listed